AN2 Therapeutics, Inc.
ANTX
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -19.84% | -24.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.21% | 39.14% | |||
| Operating Income | 7.21% | -39.14% | |||
| Income Before Tax | 6.87% | -44.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.87% | -44.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.87% | -44.74% | |||
| EBIT | 7.21% | -39.14% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 7.12% | -44.21% | |||
| Normalized Basic EPS | 7.15% | -44.21% | |||
| EPS Diluted | 7.12% | -44.21% | |||
| Normalized Diluted EPS | 7.15% | -44.21% | |||
| Average Basic Shares Outstanding | 0.27% | 0.34% | |||
| Average Diluted Shares Outstanding | 0.27% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||